Targeting BRCA1‐BER deficient breast cancer by ATM or DNA‐PKcs blockade either alone or in combination with cisplatin for personalized therapy

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Molecular Oncology

• Publication date

  2015-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.molonc.2014.08.001PMID 25205036PMCID PMC5528668
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting BRCA1‐BER deficient breast cancer by ATM or DNA‐PKcs blockade either alone or in combination with cisplatin for personalized therapy

  2015cited by this paper
• Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer

  2014influential reference
• DNA polymerase β deficiency is linked to aggressive breast cancer: A comprehensive analysis of gene copy number, mRNA and protein expression in multiple cohorts

  2014influential reference
• 3-Aminobenzamide – a PARP inhibitor enhances the sensitivity of peripheral blood micronucleus and comet assays in mice

  2014cited by this paper
• Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer

  2014cited by this paper
• Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis

  2013influential reference
• Clinicopathological significance of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancer

  2013influential reference
• Targeting XRCC1 deficiency in breast cancer for personalized therapy.

  2013influential reference
• Single-strand selective monofunctional uracil-DNA glycosylase (SMUG1) deficiency is linked to aggressive breast cancer and predicts response to adjuvant therapy

  2013influential reference
• The ATM protein kinase: regulating the cellular response to genotoxic stress, and more

  2013cited by this paper
• PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis.

  2013cited by this paper
• Mammalian Base Excision Repair: the Forgotten Archangel

  2013cited by this paper
• Clinicopathological and functional significance of XRCC1 expression in ovarian cancer

  2013influential reference
• Methylation of BRCA1 Promoter Region Is Associated with Unfavorable Prognosis in Women with Early-Stage Breast Cancer

  2013influential reference
• DNA double-strand–break complexity levels and their possible contributions to the probability for error-prone processing and repair pathway choice

  2013cited by this paper
• Interaction between DNA Polymerase β and BRCA1

  2013cited by this paper
• The role of BRCA1 in DNA double-strand repair: past and present.

  2013cited by this paper
• The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

  2012cited by this paper
• Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models

  2012cited by this paper
• Playing the end game: DNA double-strand break repair pathway choice.

  2012cited by this paper
• Mechanisms of BRCA1 tumor suppression.

  2012cited by this paper
• Mechanisms of BRCA 1 Tumor Suppression

  2012cited by this paper
• Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination

  2011cited by this paper
• Induction and repair of DNA double strand breaks: the increasing spectrum of non-homologous end joining pathways.

  2011cited by this paper
• 53BP1 promotes ATM activity through direct interactions with the MRN complex

  2010cited by this paper
• Transcriptional Regulation of the Base Excision Repair Pathway by BRCA1*

  2010cited by this paper
• A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks

  2010cited by this paper
• Cytoscape 2.8: new features for data integration and network visualization

  2010cited by this paper
• The DNA-dependent protein kinase (DNA-PK): More than just a case of making ends meet?

  2010cited by this paper
• BRCA1 and its toolbox for the maintenance of genome integrity

  2010cited by this paper
• BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair.

  2010cited by this paper
• Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase.

  2009cited by this paper
• Artificial Neural Network Based Algorithm for Biomolecular Interactions Modeling

  2009cited by this paper
• Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo

  2009cited by this paper
• DNA-Dependent Protein Kinase (DNA-PK)–Dependent Cisplatin-Induced Loss of Nucleolar Facilitator of Chromatin Transcription (FACT) and Regulation of Cisplatin Sensitivity by DNA-PK and FACT

  2009cited by this paper
• Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion

  2009cited by this paper
• Targeted therapy for cancer using PARP inhibitors.

  2008cited by this paper
• ATM-dependent nuclear accumulation of IKK-α plays an important role in the regulation of p73-mediated apoptosis in response to cisplatin

  2008cited by this paper
• Activation and regulation of ATM kinase activity in response to DNA double-strand breaks

  2007cited by this paper
• Human cancers express a mutator phenotype

  2006cited by this paper
• Good Timing in the Cell Cycle for Precise DNA Repair by BRCA1

  2005influential reference
• Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026

  2005cited by this paper
• Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts

  2005cited by this paper
• Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments

  2004cited by this paper
• Hallmarks of 'BRCAness' in sporadic cancers

  2004cited by this paper
• Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM

  2004cited by this paper
• Diagnosis of multiple cancer types by shrunken centroids of gene expression

  2002cited by this paper
• BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair

  2002influential reference
• BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II).

  1998cited by this paper
• Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy

  1995cited by this paper
• Criteria for analyzing interactions between biologically active agents.

  1981cited by this paper
• BRCA 1 induces DNA damage recognition factors and enhances nucleotide excision repair

  year unknowncited by this paper

• All roads lead to mitosis: a common requirement for DNA replication stress-dependent and -independent killing of BRCA-deficient cells.

  2025cites this paper
• Functional and clinical significance of the RNA m6A methyltransferase complex in breast cancer

  2025cites this paper
• Therapeutic innovations in triple negative breast cancer: integrating molecular targeting and monoclonal antibody strategies

  2025cites this paper
• Potential promising of synthetic lethality in cancer research and treatment

  2024influential citation
• Role of the Nrf2/ARE Pathway in the mtDNA Reparation.

  2024cites this paper
• ARF4-mediated retrograde trafficking as a driver of chemoresistance in GBM.

  2024cites this paper
• Synthetic lethal strategies for the development of cancer therapeutics

  2024cites this paper
• Unravelling the clinicopathological and functional significance of replication protein A (RPA) heterotrimeric complex in breast cancers

  2023cites this paper
• Unleashing the Power of Synthetic Lethality: Augmenting Treatment Efficacy through Synergistic Integration with Chemotherapy Drugs

  2023cites this paper
• Xrcc5/KU80 is not required for the survival or activation of prophase-arrested oocytes in primordial follicles

  2023cites this paper
• Cellular resistance mechanisms in cancer and the new approaches to overcome resistance mechanisms chemotherapy

  2023cites this paper
• Theranostic Interpolation of Genomic Instability in Breast Cancer

  2022cites this paper
• Primary Founder Mutations in the PRKDC Gene Increase Tumor Mutation Load in Colorectal Cancer

  2022cites this paper
• Kidney Cyst Lining Epithelial Cells Are Resistant to Low-Dose Cisplatin-Induced DNA Damage in a Preclinical Model of Autosomal Dominant Polycystic Kidney Disease

  2022cites this paper
• Therapeutic Opportunities of Disrupting Genome Integrity in Adult Diffuse Glioma

  2022cites this paper
• DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targets

  2021cites this paper
• The role of DNA damage response in chemo- and radio-resistance of cancer cells: Can DDR inhibitors sole the problem?

  2021cites this paper
• Untangling the clinicopathological significance of MRE11-RAD50-NBS1 complex in sporadic breast cancers

  2021cites this paper
• Targeted and systemic insights into the crosstalk between DNA-dependent protein kinase catalytic subunit and receptors of estrogen, progesterone and epidermal growth factor in the context of cancer

  2021cites this paper
• Targeting the replication stress response through synthetic lethal strategies in cancer medicine.

  2021cites this paper
• Natural products targeting cancer cell dependency

  2021cites this paper
• Adverse Reactions and Resistance of Anticancer Drug Cisplatin

  2021cites this paper
• DNA-PK in human malignant disorders: Mechanisms and implications for pharmacological interventions.

  2020cites this paper
• The Problem of Drug Resistance in Cancer Chemotherapy

  2020cites this paper
• XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib

  2020cites this paper
• Antitumor Drugs and Their Targets

  2020cites this paper
• Deregulated estrogen receptor signaling and DNA damage response in breast tumorigenesis.

  2020cites this paper
• Targeting DNA damage response kinases in cancer therapy.

  2020cites this paper
• Synthetic Lethality through the Lens of Medicinal Chemistry

  2020cites this paper
• Epigenetic based synthetic lethal strategies in human cancers

  2020cites this paper
• Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation

  2020cites this paper
• Artificial Intelligence in Pharmacoepidemiology: A Systematic Review. Part 1—Overview of Knowledge Discovery Techniques in Artificial Intelligence

  2020influential citation
• Targeting DNA-PK in cancer.

  2020cites this paper
• DNA damage repair functions and targeted treatment in breast cancer

  2020cites this paper
• Mechanisms of Multidrug Resistance in Cancer Chemotherapy

  2020cites this paper
• Targeting the DNA-PK complex: Its rationale use in cancer and HIV-1 infection.

  2019cites this paper
• Cancer risk from low dose radiation in Ptch1+/- mice with inactive DNA repair systems: Therapeutic implications for medulloblastoma.

  2019cites this paper
• Development and implementation of precision therapies targeting base-excision DNA repair in BRCA1-associated tumors

  2019influential citation
• Synergistic Effects of Olaparib and DNA-damaging Agents in Oesophageal Squamous Cell Carcinoma Cell Lines

  2019cites this paper
• Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy

  2019cites this paper
• Defective base excision repair in the response to DNA damaging agents in triple negative breast cancer

  2019cites this paper
• Acetogenins as potential checkpoint-2 kinase inhibitors: an in silico analysis

  2019cites this paper
• DMA1 AND DMA2: NOVEL REGULATORS OF DOUBLE-STRAND BREAK RESPONSE IN S. CEREVISIAE

  2019cites this paper
• DNA Repair Response Modulation Potentiates Low Dose Cisplatin Effects in HeLa Cells

  2018influential citation
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction).

  2018cites this paper
• ATM: Its Recruitment, Activation, Signalling and Contribution to Tumour Suppression

  2018cites this paper
• Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy

  2018cites this paper
• Chk1 phosphorylated at serine 345 is a predictor of early local recurrence and radio-resistance in breast cancer

  2018cites this paper
• Persistent DNA strand breaks induce a CAF-like phenotype in normal fibroblasts

  2018cites this paper
• Synthetically Lethal Interactions of ATM, ATR, and DNA-PKcs.

  2018cites this paper
• DNA repair pathways and cisplatin resistance: an intimate relationship

  2018cites this paper
• Estrogen receptor-α promoter methylation is a biomarker for outcome prediction of cisplatin resistance in triple-negative breast cancer

  2017cites this paper
• DNA-dependent protein kinase catalytic subunit functions in metastasis and influences survival in advanced-stage laryngeal squamous cell carcinoma

  2017cites this paper
• DNA Base Excision Repair: The Achilles' Heel of Tumour Cells and their Microenvironment?

  2017cites this paper
• Molecular approaches to potentiate cisplatin responsiveness in carcinoma therapeutics

  2017cites this paper
• Simultaneous targeting of ATM and Mcl-1 increases cisplatin sensitivity of cisplatin-resistant non-small cell lung cancer

  2017cites this paper
• Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression

  2017cites this paper
• Targeting ATR in cancer medicine.

  2017cites this paper
• DNA damage repair in breast cancer and its therapeutic implications.

  2017cites this paper
• Not breathing is not an option: How to deal with oxidative DNA damage.

  2017cites this paper
• Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers

  2017cites this paper
• Aberrant DNA Double-strand Break Repair Threads in Breast Carcinoma: Orchestrating Genomic Insult Survival

  2016cites this paper
• Novel Immunohistochemical Based Biomarkers in Breast Cancer

  2016cites this paper
• APE1 polymorphic variants cause persistent genomic stress and affect cancer cell proliferation

  2016cites this paper
• DNA-PKcs: A promising therapeutic target in human hepatocellular carcinoma?

  2016cites this paper
• Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers

  2016cites this paper
• ATM kinase inhibitor KU-55933 contribution in cisplatin mediated HeLa proliferation

  2016cites this paper
• Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio‐resistance in breast cancer

  2016cites this paper
• Cancer TARGETases: DSB repair as a pharmacological target.

  2016cites this paper
• Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer

  2015cites this paper
• BRCA1: Beyond double-strand break repair.

  2015cites this paper
• Embracing synthetic lethality of novel anticancer therapies

  2015cites this paper
• ATM and ATR as therapeutic targets in cancer.

  2015cites this paper
• Preventing Damage Limitation: Targeting DNA-PKcs and DNA Double-Strand Break Repair Pathways for Ovarian Cancer Therapy

  2015cites this paper
• A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients

  2015cites this paper
• Targeting BRCA1‐BER deficient breast cancer by ATM or DNA‐PKcs blockade either alone or in combination with cisplatin for personalized therapy

  2015cites this paper
• DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers

  2015cites this paper
• Teicher ATM and ATR as therapeutic targets in cancer

  2015influential citation
• Initiation of the ATM-Chk2 DNA damage response through the base excision repair pathway.

  2015cites this paper
• Clinicopathological Significance of ATM-Chk2 Expression in Sporadic Breast Cancers: a Comprehensive Analysis in Large Cohorts

  2014cites this paper